Abstract
Idiopathic cervical dystonia (ICD) is the most common adult-onset focal dystonia. It is characterised by relatively sustained, involuntary contractions of neck muscles. Injections of botulinum toxin (BTX)-A are safe and effective for the treatment of ICD, and have substantially improved its treatment. BTX-A is manufactured by Allergan Pharmaceuticals in the US and Ireland, and is distributed as Botox®. In Europe, BTX-A is manufactured and distributed by Ipsen Pharmaceuticals as Dysport®. Success rates for BTX-A injections for ICD ranges 64 - 90%, with 76 - 93% of injected patients experiencing pain reduction. Side effects are generally mild and include dysphagia and neck weakness. 2004
Original language | English |
---|---|
Pages (from-to) | 2017-2024 |
Number of pages | 8 |
Journal | Expert Opinion on Pharmacotherapy |
Volume | 5 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2004 |
Scopus Subject Areas
- Pharmacology
- Pharmacology (medical)
Keywords
- Botox
- Botulinum toxin A
- Cervical dystonia
- Dysport